Propanc Biopharma, Inc. (PPCB)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 10:30AM EDT. Market open.
| Previous close | 0.0028 |
| Open | 0.0028 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0026 - 0.0030 |
| 52-week range | 0.0018 - 0.0500 |
| Volume | |
| Avg. volume | 18,260,780 |
| Market cap | 342,143 |
| Beta (5Y monthly) | 1.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada
MELBOURNE, Australia, August 03, 2022--Mrs Belén Toledo Cutillas MSc, has been investigating an important thesis on effects of proenzyme therapy and the impact on the tumor microenvironment
- Business Wire
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
MELBOURNE, Australia, July 28, 2022--Rather than kill cancer cells like most therapies, PRP induces cancer cells to differentiate so they are no longer malignant and die off naturally
- Business Wire
Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program
MELBOURNE, Australia, July 19, 2022--The POP1 program is designed to produce a backup clinical compound to the Company’s lead product candidate, PRP, which is targeting metastatic cancer
© 2022 Yahoo. All rights reserved.
